Jeremy Carlson
Nephrology · Jacksonville, FLNPI 1932562832
Payments from drug & device makers
Across 297 payments — averaging $352.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$66K
- Boehringer Ingelheim$19K
- Bayer$15K
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$543
- Bard Peripheral Vascular, Inc.$291
- plus $2K from 24 others
What the payments were for
- Consulting fees$1,5391%
- Speaking & faculty fees$96,59892%
- Travel & lodging$4050%
- Food & beverage$5,9186%
- Education$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 96 | $65,941 |
| Boehringer Ingelheim | 36 | $19,447 |
| Bayer | 32 | $14,816 |
| AstraZeneca(2 entities) | 38 | $1,313 |
| Otsuka America Pharmaceutical, Inc. | 24 | $543 |
| Bard Peripheral Vascular, Inc. | 4 | $291 |
| Aurinia Pharma U.S., Inc. | 4 | $281 |
| OPKO Pharmaceuticals, LLC | 6 | $274 |
| Calliditas Therapeutics US Inc. | 3 | $207 |
| Travere Therapeutics, Inc. | 7 | $201 |
| Vifor Pharma, Inc. | 10 | $196 |
| Corcept Therapeutics | 5 | $196 |
| Amgen | 4 | $185 |
| Novartis | 5 | $145 |
| Medtronic | 1 | $144 |
| Nxstage Medical, Inc. | 1 | $91 |
| Outset Medical Inc | 1 | $71 |
| Merck | 3 | $58 |
| GSK | 2 | $49 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Novo Nordisk | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Ardelyx, Inc. | 1 | $29 |
| GRT US Holding, Inc. | 1 | $28 |
| Lundbeck LLC | 2 | $27 |
| Akebia Therapeutics Inc | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,735 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $88,540 |
| RayaldeeCalcifediol | 32 | $42,116 |
| FarxigaDapagliflozin Propanediol | 33 | $39,803 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $24,231 |
| KerendiaFinerenone | 11 | $17,406 |
| Torsemide | 84 | $2,130 |
| Chlorthalidone | 88 | $1,693 |
| Bumetanide | 23 | $832 |
| Amlodipine Besylate | 87 | $716 |
| Carvedilol | 87 | $687 |
| Losartan Potassium | 119 | $645 |
| Potassium Chloride | 25 | $636 |
| Minoxidil | 16 | $533 |
| Nifedipine ErNifedipine | 25 | $525 |
| Lisinopril | 79 | $416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19,447 | $88,54062 claims |
| AstraZenecaFarxiga, Lokelma | $1,313 | $64,03452 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $274 | $42,11632 claims |
| BayerKerendia | $14,816 | $17,40611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.
Other nephrology in Jacksonville
- Fouad ChebibJacksonville$821K
- Craig ShapiroJacksonville$610K
- Nabeel AslamJacksonville$389K
- Ivan PorterJacksonville$342K
- Prasanth KrishJacksonville$340K
- Deborah PriceJacksonville$321K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.